Opendata, web and dolomites

LITMUS SIGNED

Liver Investigation: Testing Marker Utility in Steatohepatitis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LITMUS project word cloud

Explore the words cloud of the LITMUS project. It provides you a very rough idea of what is the project "LITMUS" about.

academics    remit    complicating    laid    conduct    limited    fibrosis    biopsy    capability    costly    identification    invasive    pharmaceutical    flip    developers    qualification    procedure    robustly    bioresources    patient    risk    independent    epos    partite    hampered    overarching    performance    technologies    centres    obesity    stage    clinicians    risky    validation    definitive    recognised    care    strongly    datasets    nafld    impartial    members    commercial    amongst    academic    disease    collaborations    validity    liver    imi    internationally    supporting    regulatory    epidemics    inter    delivering    diabetes    clinical    ema    tri    evaluation    alcoholic    substantial    greatest    noninvasive    clear    omics    fulfil    pace    rate    monitor    successful    medical    worldwide    drug    powered    scientific    progression    biomarker    litmus    demonstrable    fda    impeded    validate    lack    trials    foundations    industry    biomarkers    expertise    fatty    stratify    platform    advantage    oriented    experts    cohorts    healthcare    severity    diagnose    accelerating    clarity    nash    variability   

Project "LITMUS" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF NEWCASTLE UPON TYNE 

Organization address
address: KINGS GATE
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU
website: http://www.ncl.ac.uk/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.litmus-project.eu
 Total cost 47˙281˙406 €
 EC max contribution 15˙797˙881 € (33%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2016-09-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2017
 Duration (year-month-day) from 2017-11-01   to  2022-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF NEWCASTLE UPON TYNE UK (NEWCASTLE UPON TYNE) coordinator 2˙897˙911.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙818˙750.00
3    NORDIC BIOSCIENCE A/S DK (HERLEV) participant 1˙427˙093.00
4    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 1˙180˙910.00
5    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) participant 1˙073˙015.00
6    INST CARDIOMETABOLISME NUTRITION ICAN FR (PARIS) participant 684˙250.00
7    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 638˙130.00
8    SERVICIO ANDALUZ DE SALUD ES (SEVILLA) participant 601˙250.00
9    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 540˙033.00
10    UNIVERSITAET BERN CH (BERN) participant 435˙000.00
11    UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT DE (WURZBURG) participant 406˙206.00
12    ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS ES (DERIO VIZCAYA) participant 403˙017.00
13    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 365˙160.00
14    IXSCIENT LIMITED UK (TWICKENHAM MIDDLESEX) participant 344˙375.00
15    OREBRO UNIVERSITY SE (OREBRO) participant 312˙500.00
16    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 273˙328.00
17    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 260˙500.00
18    PERSPECTUM LTD UK (OXFORD) participant 250˙000.00
19    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 248˙076.00
20    ANTAROS MEDICAL AB SE (MOLNDAL) participant 231˙275.00
21    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) participant 202˙500.00
22    UNIVERSITAIR ZIEKENHUIS ANTWERPEN BE (EDEGEM) participant 167˙100.00
23    UNIVERSITE D'ANGERS FR (ANGERS CEDEX 01) participant 122˙500.00
24    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 118˙350.00
25    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 118˙115.00
26    UNIVERSITA DEGLI STUDI DI PALERMO IT (PALERMO) participant 105˙081.00
27    LINKOPINGS UNIVERSITET SE (LINKOPING) participant 99˙600.00
28    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) participant 80˙722.00
29    UNIVERSITA CATTOLICA DEL SACRO CUORE IT (MILANO) participant 80˙653.00
30    FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA PT (LISBOA) participant 78˙487.00
31    EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER CH (ZURICH) participant 61˙680.00
32    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 61˙263.00
33    Faculdade de Farmácia da Universidade de Lisboa PT (Lisboa) participant 56˙968.00
34    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 54˙075.00
35    ONE WAY LIVER SL ES (DERIO BIZKAIA) participant 1.00
36    ALLERGAN LIMITED UK (MARLOW) participant 0.00
37    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
38    BOEHRINGER INGELHEIM INTERNATIONALGMBH DE (INGELHEIM) participant 0.00
39    BRISTOL-MYERS SQUIBB COMPANY CORP US (NEW YORK) participant 0.00
40    ECHOSENS FR (PARIS) participant 0.00
41    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
42    ELLEGAARD GOTTINGEN MINIPIGS AS DK (DALMOSE) participant 0.00
43    EXALENZ BIOSCIENCE LTD IL (MODIIN) participant 0.00
44    GENFIT FR (LOOS) participant 0.00
45    GILEAD SCIENCES INC US (FOSTER CITY CA) participant 0.00
46    HISTOINDEX PTE LTD SG (SINGAPORE) participant 0.00
47    INTERCEPT PHARMA EUROPE LTD UK (BRISTOL) participant 0.00
48    NORDIC BIOSCIENCE COMPOUND DEVELOPMENT A/S DK (Helev) participant 0.00
49    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
50    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
51    PFIZER LIMITED UK (SANDWICH) participant 0.00
52    RESEARCH TRIANGLE INSTITUTE US (RESEARCH TRIANGLE PARK) participant 0.00
53    RESOUNDANT, INC. US (ROCHESTER) participant 0.00
54    SANOFI-AVENTIS DEUTSCHLAND GMBH DE (FRANKFURT AM MAIN) participant 0.00
55    SOMALOGIC INC US (BOULDER COLORADO) participant 0.00
56    TAKEDA DEVELOPMENT CENTRE EUROPE LTD UK (LONDON) participant 0.00

Map

 Project objective

Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. It is currently assessed by liver biopsy, an invasive, costly and risky procedure. The lack of noninvasive biomarkers has hampered patient care and impeded drug development by complicating conduct of clinical trials.The overarching aim of LITMUS is to develop, robustly validate and advance towards regulatory qualification biomarkers that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. This will be achieved through a goal-oriented, tri-partite collaboration delivering a definitive and impartial evaluation platform for biomarkers, bringing together: (i) End-users of biomarker technologies (clinicians with expertise in NAFLD and the pharmaceutical industry)? (ii) Independent academics with expertise in the evaluation of medical test/biomarker performance? and (iii) Biomarker researchers and developers (academic or commercial).

LITMUS has the demonstrable capability to fulfil the IMI call remit. Built upon foundations laid by the EU-funded FLIP/EPoS projects and long-established, successful scientific collaborations amongst many of Europe’s leading clinical-academic centres, LITMUS is at a unique advantage due to its existing large-scale patient cohorts, bioresources and multi-omics datasets. Consortium members are internationally recognised experts with substantial relevant expertise supporting the program’s clear focus on biomarker identification, validation and accelerating EMA/FDA qualification. Thus, LITMUS is powered to provide clarity on biomarker validity for NAFLD at scale and pace: supporting drug development and the targeting of medical care and limited healthcare resources to those at greatest need.

 Deliverables

List of deliverables.
Detailed plan for submission of biomarkers to the regulatory authorities (EMA and FDA) for qualification Documents, reports 2020-04-07 22:18:02
SOPs for collection, processing and storage of whole blood, EDTA plasma, SST serum, urine, stool, frozen liver biopsies Documents, reports 2020-04-07 22:18:03
Imaging manual to standardise image acquisition across all participating sites Documents, reports 2020-04-07 22:18:03
Project Handbook Documents, reports 2020-04-07 22:18:03
Risk assessment procedure Documents, reports 2020-04-07 22:18:03
Report describing minimally acceptable performance criteria for diagnostic testing Documents, reports 2020-04-07 22:18:03
Detailed dissemination plan Documents, reports 2020-04-07 22:18:02
An optimised histological staging system for NAFLD-associated fibrosis Documents, reports 2020-04-07 22:18:02
LITMUS Data Management Plan Documents, reports 2020-04-07 22:18:02

Take a look to the deliverables list in detail:  detailed list of LITMUS deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LITMUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LITMUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More